Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

CCClaudia CrippaARAldo RoccaroATAlessandra Tucci

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows ASCT effects on outcomes in older multiple myeloma patients, indicating frailty status impacts treatment.

Key Points

  • This research aims to re-evaluate the role of ASCT in elderly patients with multiple myeloma considering new anti-CD38 therapies.
  • Retrospective comparison of transplant-eligible and non-transplant eligible patients.
  • Analysis included 122 patients aged 65–75 with newly diagnosed multiple myeloma.
  • Evaluated response rates, progression-free survival, overall survival, and treatment-related toxicity.
  • Response rate was 94% in the ASCT cohort vs 91% in the no-ASCT cohort.
  • Frailty status impacted progression-free survival significantly in the no-ASCT cohort.
  • Neutropenia was significantly more frequent in the ASCT cohort, affecting 92% of patients.

Cite This Study

Crippa et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da83https://doi.org/10.1182/blood-2025-4040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML?2026
  2. 2Feasibility and outcome of first-line autotransplant-based treatment in newly diagnosed multiple myeloma patients aged > 65 years: monocentric retrospective real-world analysis2024
  3. 3Efficacy and safety of autologous stem cell transplantation in first-line treatment and at relapse in elderly patients with multiple myeloma2024
  4. 4Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia2025
  5. 5Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).2004 · 1 citations